First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.

CervoMed's stock soars 400% on promising dementia drug data. See more on insights, potential concerns, and what it means for ...

ZyVersa Therapeutics (NASDAQ:ZVSA – Get Free Report) is expected to be announcing its earnings results before the market ...

A recent study challenges the effectiveness of microdosing LSD for treating ADHD. Despite self-reported improvements, the ...

Discover recent clinical trial failures in depression and explore potential pathways for advancing antidepressant drug ...

Study results support the role of functional dystrophin and suggest that delandistrogene moxeparvovec stabilizes or slows ...

Soligenix, Inc. (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ...

Immuneering is a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients. The Company’s lead product candidate, IMM-1-104 ...

Pliant Therapeutics has discontinued a pivotal Phase 2b/3 clinical trial evaluating bexotegrast as an IPF treatment.

The essential thrombocythemia market is on a growth trajectory, driven by increasing diagnosis rates, aging population ...

Researchers at the University of Tsukuba have investigated the changes in the primary evaluation items in phase II clinical ...

Bullish option flow detected in Bristol Myers ( BMY) Squibb with 11,821 calls trading, 2x expected, and implied vol increasing almost 2 points to 27.82%. May-25 67.5 calls and Mar-25 60 calls are the ...